Health

  • April 14, 2026

    Ga. Providers Say Rutledge Bars United's Preemption Win

    Medical providers are urging a Georgia federal court to deny United's bid for an early win in its case seeking a declaration that the providers' purported attempt to claw back reimbursements for out-of-network services are preempted, arguing that state-law claims involving employee benefits aren't preempted by federal benefits law.

  • April 14, 2026

    Meta, Others Can't Look At Internal Data To Probe Jury Pool

    A California federal judge on Tuesday granted an uncontested bid by school district plaintiffs to bar Meta and other social media companies from using nonpublic information — including their internal data — to investigate potential jurors for an upcoming bellwether trial in multidistrict litigation over the alleged harms of social media addiction.

  • April 14, 2026

    Wash. Appeals Court Revives Podiatrist Trade Secrets Case

    An appeals court in Washington state has reinstated a case brought by a Seattle-area podiatry practice against a former employee accused of stealing patient data for his separate practice.

  • April 14, 2026

    FDA Offers Guidance On Safety Testing For Gene-Editing Tech

    The U.S. Food and Drug Administration on Tuesday issued draft guidance recommending steps drug companies should take to evaluate the safety of gene-editing technology as they seek federal approval for cutting-edge treatments aimed at genetic diseases.

  • April 14, 2026

    IHC's Ch. 11 Mediation Ask 'Jumped The Gun,' Creditors Say

    Lenders and unsecured creditors to Inspired Healthcare Capital have told a Texas bankruptcy court it is too soon in the senior-living facility group's Chapter 11 case to appoint a mediator, arguing its mandatory mediation proposal could bind creditors' rights.

  • April 14, 2026

    Eli Lilly To Purchase Cooley-Led CrossBridge In $300M Deal

    Venture-backed pre-clinical biotechnology firm CrossBridge Bio Inc., advised by Cooley LLP, on Tuesday announced that it has agreed to be bought by pharmaceutical giant Eli Lilly & Co. in a deal worth up to $300 million.

  • April 14, 2026

    7th Circ. Suggests High Court Ruling Supports Ark. PBM Rule

    The Seventh Circuit appeared reluctant Tuesday to revive a union fund's challenge to an Arkansas rule making health plans disclose pharmacy compensation and pay fees, with judges pointing to a 2020 U.S. Supreme Court ruling that permitted state cost regulations on pharmacy benefit managers.

  • April 14, 2026

    Ginsburg Hack Conviction Upheld For Man Who Blamed Cat

    The Fourth Circuit affirmed Tuesday a former hospital transplant coordinator's conviction for illegally accessing U.S. Supreme Court Justice Ruth Bader Ginsburg's healthcare records, upholding a ruling that the defendant was not improperly coerced when he told FBI agents a coworker or his cat may have been responsible.

  • April 14, 2026

    Mich. AG Says PBMs Can't Duck Drug-Pricing Suit

    Two pharmacy benefit managers can't dodge an antitrust lawsuit accusing them of price-fixing reimbursement rates because Michigan has properly claimed an antitrust violation, state Attorney General Dana Nessel told a federal court, asking it to toss aside the PBMs' dismissal bid. 

  • April 14, 2026

    4th Circ. Won't Rehear Allergan Overcharge Suit

    The Fourth Circuit on Tuesday denied a rehearing petition lodged after a panel revived a whistleblower suit accusing an Allergan Sales LLC predecessor of overcharging Medicaid.

  • April 14, 2026

    Buyers Seek Final Approval Of $4.85M Bayer Benzene Deal

    A class of consumers is asking a New Jersey federal court to give final approval of a $4.85 million settlement to resolve claims that Bayer US LLC's antifungal products were contaminated with benzene.

  • April 14, 2026

    Colo. Supplement Co. Sent Unwanted Texts, Suit Says

    A Colorado dietary supplement company violated the Telephone Consumer Protection Act by bombarding consumers with unsolicited telemarketing text messages despite their numbers being listed on the national Do Not Call Registry, according to a proposed class action filed Tuesday in Colorado federal court.

  • April 14, 2026

    Avanos Medical Going Private In $1.3B Deal Led By 3 Firms

    American Industrial Partners has agreed to acquire Avanos Medical Inc. in an all-cash transaction valued at nearly $1.3 billion, a take-private deal steered by three law firms, Avanos announced Tuesday. 

  • April 14, 2026

    State AGs, Albertsons Chain Reach $773M Opioid Deal

    Albertsons Cos. Inc. and the attorneys general of California, Colorado, Illinois and Oregon on Tuesday said that the pharmacy and grocery chain had agreed to a $773 million settlement in principle to end claims brought by states, local governments and Native American tribes over its role in the opioid crisis.

  • April 14, 2026

    Vehicle Co. Inks $150K Deal To End Tobacco Fee Suit

    International Motors LLC, formerly Navistar, has agreed to pay $150,000 to resolve a suit claiming the company illegally charged workers an extra $600 a year if they used tobacco without giving them a proper avenue to dodge the fee, according to an Illinois federal court filing.

  • April 14, 2026

    Omnicare OK'd For Ch. 11 Auction With $250M Base Bid

    Pharmacy services provider Omnicare's choice of a $250 million stalking horse bid for its assets was approved Tuesday by a Texas bankruptcy judge, setting up a possible auction in May.

  • April 14, 2026

    Screening Time Deal Doesn't Bar Break Suit, Wash. Panel Says

    An eldercare company's class settlement over COVID-19 screening time doesn't bar a separate suit claiming the company failed to pay workers for missed meal breaks, a Washington state appeals court ruled, reviving the break claims.

  • April 13, 2026

    Cannabis Giant Verano Accused Of Mishandling Patient Info

    Cannabis giant Verano exposed the private data of at least half a million of its medical marijuana customers, according to a proposed class action removed to federal court that alleges the company turned ordinary receipts into "highly sensitive medical records."

  • April 13, 2026

    Ill. Judge Wants More Proof To Recalculate Kickback Damages

    An Illinois federal judge tasked with recalculating damages from a home health company's referral kickback scheme said Monday that she needs more complete and reliable evidence to help determine the appropriate amount, but allowed the government to continue offsetting Medicare payments as part of its judgment collection bid.

  • April 13, 2026

    FTC Ends Teen Height Growth Supplement Claims

    A supplement maker and its owners agreed to pay $750,000 to end claims they misled customers into thinking their products could make their children taller, the Federal Trade Commission announced on Monday.

  • April 13, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    Massachusetts legislators sent a bill making numerous changes to the state's cannabis regulatory scheme to the governor, Oregon and Louisiana advanced legislation to expand medical marijuana access to seriously ill patients in healthcare facilities, and Virginia's governor approved legislation paving the way for medical psilocybin if the drug's federal status should change. Here are the major moves in cannabis and psychedelics legislation from the past week.

  • April 13, 2026

    Del. Judge Ends 80K Pre-2026 Zantac Cases

    A Delaware state court on Monday dismissed more than 80,000 suits filed before December alleging that Boehringer Ingelheim's discontinued heartburn medication Zantac caused cancer, following a Delaware Supreme Court ruling on admissibility of the plaintiffs' experts.

  • April 13, 2026

    'Gay Conversion' Ruling Nixes Telehealth Ban, 9th Circ. Told

    An attorney representing a doctor and patient challenging California's law severely limiting interstate telehealth medical consultations urged a Ninth Circuit panel Monday to reverse a lower court's order dismissing the suit, saying the Supreme Court's recent decision nullifying Colorado's ban on "gay conversion therapy" applies to the case.

  • April 13, 2026

    Obesity Drugmaker Leads 2 Biotech Startups Eyeing IPOs

    Two biotechnology startup companies on Monday filed plans for their public debuts, with obesity-focused Kailera Therapeutics planning to raise an estimated $500 million in its initial public offering and protein biomarker detection platform Alamar Biosciences planning to raise around $150 million.

  • April 13, 2026

    Mylan Can't Revive Copaxone Antitrust Claims Against Teva

    A New Jersey federal judge sided Monday with a special master's recommendations to nix some of the parallel claims from Mylan and retailers like Walgreens accusing Teva of using regulatory deception, false advertising, improper rebates and more to delay generic competition to its Copaxone multiple sclerosis treatment.

Expert Analysis

  • To Survive FCA Actions, Small Cos. Must Take Offensive Steps

    Author Photo

    A fumbled response to False Claims Act allegations can doom lower-middle-market businesses, and with FCA enforcement hitting record levels for two years, smaller companies must have offensive strategies ready that focus their limited resources on defeating civil qui tam and federal criminal actions, says Derrelle Janey at Olshan Frome.

  • The Law Firm Merger Diaries: Leadership Strategy After Day 1

    Author Photo

    For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.

  • How US Liability Law Is Becoming The Primary Regulator Of AI

    Author Photo

    Comprehensive federal AI regulation remains fragmented and uncertain — but U.S. courts, applying long-standing doctrines of liability and responsibility, are actively shaping how AI systems are designed, deployed and governed, and companies are aligning their AI practices because courts may hold them accountable if they do not, says Alexander Lima at Wesco International.

  • Record FCA Recoveries Signal Intensified Healthcare Focus

    Author Photo

    In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.

  • Fed. Circ. In Jan.: On The Validity Of Expert Testimony

    Author Photo

    The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.

  • Methods For Challenging State Civil Investigative Demands

    Author Photo

    Ongoing challenges to enforcement actions underscore the uphill battle businesses face in arguing that a state investigation is prohibited by federal law, but when properly deployed, these arguments present a viable strategy to resist civil investigative demands issued by state attorneys general, say attorneys at Troutman Pepper.

  • Calif.'s Civility Push Shows Why Professionalism Is Vital

    Author Photo

    The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.

  • A Potential Shift In FDA's Approach To Drug Trial Design

    Author Photo

    Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.

  • Opinion

    SNAP Rule Confusion Risks A Compliance Crisis

    Author Photo

    Recent Supplemental Nutrition Assistance Program food restriction waivers pose a compliance crisis for legal practitioners advising food retailers, amid higher costs and lack of a coherent national standard, says Tyson-Lord Gray at Yeshiva University’s Benjamin N. Cardozo School of Law.

  • Series

    Trivia Competition Makes Me A Better Lawyer

    Author Photo

    Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.

  • What FDA Guidance Means For Future Of Health Software

    Author Photo

    Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.

  • Opinion

    Federal Preemption In AI And Robotics Is Essential

    Author Photo

    Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.

  • Series

    Law School's Missed Lessons: What Cross-Selling Truly Takes

    Author Photo

    Early-career attorneys may struggle to introduce clients to practitioners in other specialties, but cross-selling becomes easier once they know why it’s vital to their first years of practice, which mistakes to avoid and how to anticipate clients' needs, say attorneys at Moses & Singer.

  • How State FCA Activity May Affect Civil Fraud Enforcement

    Author Photo

    A growing trend of state attorneys general enforcing their False Claims Act analogues independently of the U.S. Department of Justice carries potential repercussions for civil fraud enforcement and qui tam litigation considerations, say Li Yu at Bernstein Litowitz, Ellen London at London & Naor and Gwen Stamper at Vogel Slade.

  • Wage-Based H-1B Rule Amplifies Lottery Risks For Law Firms

    Author Photo

    Under the wage-based H-1B lottery rule taking effect Feb. 27, law firms planning to hire noncitizen law graduates awaiting bar admission should consider their options, as the work performed by such candidates may sit at the intersection of multiple occupational classifications with differing chances of success, says Jun Li at Reid & Wise.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.